Is Anteris Technologies Global Corp. Common Stock a good investment? Anteris Technologies Global Corp. Common Stock (AVR) is currently trading at 6.12 USD. Market analysts have a consensus price target of 14.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Anteris Technologies Global Corp. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.15.
No, it does not currently pay a dividend.
Anteris Technologies Global Corp. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.95.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Community Discussion